CSPC Pharmaceuticals Group Ltd.
 
 
 
 
公司概覽
業務類別 --
業務概覽 CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.
公司地址 No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
電話號碼 +86 31187037015
傳真號碼 +86 31187039608
公司網頁 https://www.cspc.com.hk
員工數量 19700
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Cuilong Zhang Director and President -- 28/04/2026
Mr. Zhenguo Wang Director and President -- 28/04/2026
Mr. Huaiyu Wang Director and President -- 28/04/2026
Dr. Chunlei Li Director, President and Chief Scientist -- 28/04/2026
Mr. Xin Cai Director and President -- 28/04/2026
Mr. Weiping Chen Director and President -- 28/04/2026
Dr. Lei Cai Vice Chairman of the Board, President and Chief Executive Officer -- 28/04/2026
Mr. Qingjie Wei Vice Chairman of the Board, President and Chief Operating Officer -- 28/04/2026
Mr. Zhiyong Qu Director and President -- 28/04/2026
Mr. Yiwei Zhang Director and President -- 28/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Chun Kwok Alan Au Independent Director 28/04/2026
Mr. Cheuk Kin Stephen Law Independent Director 28/04/2026
Mr. Dongchen Cai Executive Chairman of the Board 28/04/2026
Mr. Cuilong Zhang Director and President 28/04/2026
Mr. Zhenguo Wang Director and President 28/04/2026
Mr. Huaiyu Wang Director and President 28/04/2026
Dr. Chunlei Li Director, President and Chief Scientist 28/04/2026
Mr. Bo Wang Independent Director 28/04/2026
Mr. Chuan Chen Independent Director 28/04/2026
Professor Hongguang Wang Independent Director 28/04/2026
Ms. Quan Li Independent Director 28/04/2026
Dr. Bing Yao Director 28/04/2026
Mr. Xin Cai Director and President 28/04/2026
Mr. Weiping Chen Director and President 28/04/2026
Dr. Lei Cai Vice Chairman of the Board, President and Chief Executive Officer 28/04/2026
Mr. Qingjie Wei Vice Chairman of the Board, President and Chief Operating Officer 28/04/2026
Mr. Zhiyong Qu Director and President 28/04/2026
Mr. Yiwei Zhang Director and President 28/04/2026
 
所屬ETF (更新日期: 31/10/2026 03:04)
代號 名稱 佔比% ▼ 持有日期
IQSINYLI Candriam International Equity ETF0.001%31/07/2026
BKFiShares MSCI BIC ETF0.001%30/09/2026
GXUSGoldman Sachs MarketBeta(R) Ttl IntEqETF0.001%30/09/2026
EEMXState Street® SPDR®MSCIEMFsslFlRsrvFrETF0.001%30/09/2026
TLTENorthern Trust Mstar Em Mkts Fac Tlt ETF0.001%30/09/2026
MEMAMan Active Emerging Mkts Alt ETF0.001%30/09/2026
DFEVDimensional Emerging Markets Value ETF0.001%30/09/2026
DBEMXtrackers MSCI Em Mkts Hdg Eq ETF0.001%30/09/2026
RWEMRayliant NxtGen Multifactor EM Eq ETF0.001%30/09/2026
DBAWXtrackers MSCI All World exUS Hdg Eq ETF0.001%30/09/2026
LDEMiShares® ESG MSCI EM Leaders ETF0.001%30/09/2026
NTSEWisdomTree Emerging Mkts Effcnt Cr ETF0.0004%30/09/2026
EVLUiShares MSCI Emerging Mkts Val Fac ETF0.0004%30/09/2026
FLAXFranklin FTSE Asia ex Japan ETF0.0004%30/09/2026
IFLRInnovator International Dev Mgd Flr ETF0.0003%30/09/2026
GEMQGoldman Sachs Data Enhanced EM EquityETF0.0002%30/09/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.0002%30/09/2026
PBEEInvesco PureBeta FTSE Emerging Mkts ETF0.0002%31/05/2023
BREEMFS Blended Research Em Mkts Eq ETF0.0002%30/09/2026
ENHEiShares Enhanced Emerging Mkts Actv ETF0.0002%30/09/2026
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.